Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PHE885 |
Synonyms | |
Therapy Description |
PHE885 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting BCMA (TNFRSF17), which may lead to antitumor activity (Blood (2021) 138 (Supplement 1): 3864). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PHE885 | PHE-885|PHE 885|Autologous Anti-BCMA CAR T-cells PHE885 | PHE885 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting BCMA (TNFRSF17), which may lead to antitumor activity (Blood (2021) 138 (Supplement 1): 3864). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05172596 | Phase II | PHE885 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | ITA | FRA | ESP | DEU | 6 |
NCT04318327 | Phase I | PHE885 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |